Close Menu

Biocept

The headline has been corrected to state that Biocept's first quarter revenues decreased, not increased, 20 percent.
NEW YORK (GenomeWeb) – Newly publicly traded firm Biocept yesterday reported a 20 percent drop year over year in its first quarter revenues.

NEW YORK (GenomeWeb) – Biocept has entered into a $10 million loan and security agreement with Oxford Finance, the San Diego-based oncology diagnostics firm said in a US Securities and Exchange document on Tuesday.

UK's CHMP Grants Positive Review of MEK Inhibitor Melanoma Drug Mekinist
The UK's Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission grant marketing authorization to GlaxoSmithKline's Mekinist (trametinib).

NEW YORK (GenomeWeb News) – Oncology diagnostics company Biocept said on Friday that its revenues for 2013 increased 23 percent year over year.

NEW YORK (GenomeWeb News) – Biocept said after the close of the market on Monday that it has closed its initial public offering, raising $19 million in gross proceeds.

NEW YORK (GenomeWeb News) – Biocept today went public as shares of its common stock began trading at $10, the low end of an anticipated price range on its initial public offering.

Becton Dickinson disclosed during its fiscal fourth quarter and full-year earnings call several changes to its executive leadership.

NEW YORK (GenomeWeb News) – Biocept today set the price range on its planned initial public offering, saying it expects to price its shares between $10 and $12.

NEW YORK (GenomeWeb News) – Circulating tumor cell-based diagnostics firm Biocept on Monday filed with US regulators to go public with an initial public offering intended to raise up to $24.25 million.

Biocept Laboratories, a San Diego-based oncology laboratory specializing in circulating tumor cells and biomarker analysis, has developed a pair of PCR-based assay technologies that it claims can identify and quantify single mutations in a background of between 10,000 and 100,000

Pages

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.